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Genetic polymorphisms can partially explain the large 
inter-individual variation in DNA adduct levels following 
exposure to polycyclic aromatic hydrocarbons. Effects of 
genetic polymorphisms on DNA adduct formation are dif-
ficult to assess in human studies because exposure misclas-
sification attenuates underlying relationships. Conversely, 
ex vivo studies offer the advantage of controlled exposure 
settings, allowing the possibility to better elucidate geno-
type–phenotype relationships and gene–gene interactions. 
Therefore, we exposed lymphocytes of 168 non-smoking 
volunteers ex vivo to the environmental pollutant benzo(a)
pyrene (BaP) and BaP-related DNA adducts were quan-
tified. Thirty-four genetic polymorphisms were assessed 
in genes involved in carcinogen metabolism, oxidative 
stress and DNA repair. Polymorphisms in catalase (CAT, 
rs1001179) and cytochrome P450 1B1 (CYP1B1, rs1800440) 
were significantly associated with DNA adduct levels, 
especially when combined. Moreover, reverse transcrip-
tion–polymerase chain reaction (RT–PCR) analysis in a 
subset of 30 subjects revealed that expression of catalase 
correlated strongly with expression of CYP1B1 (R = 0.92, 
P < 0.001). To further investigate the mechanism by which 
catalase influences CYP1B1 and how they simultaneously 
affect BaP-related DNA adduct levels, catalase expression 
was transiently knocked down in the human lung epithe-
lial cell line A549. Although catalase knockdown did not 
immediately change CYP1B1 gene expression, recovery of 
catalase expression 8 h after the knockdown coincided with 
a 2.2-fold increased expression of CYP1B1 (P < 0.05). We 
conclude that the genetic polymorphism in the promoter 
region of CAT may determine the amount and activity of 
catalase, which may subsequently regulate the expression 
of CYP1B1. As a result, both genetic polymorphisms modu-
late DNA adduct levels in lymphocytes by BaP ex vivo.
Introduction
Genetic stability is challenged by many factors, including 
exposure to genotoxic chemical compounds such as polycyclic 
aromatic hydrocarbons (PAHs). PAHs such as benzo(a)pyrene 
(BaP) are widely distributed environmental contaminants that 
are able to upregulate a multitude of genes, including the cyto-
chrome P450 isoforms CYP1A1 and CYP1B1. These enzymes 
metabolise BaP to more soluble and excretable products but 
at the same time activate certain metabolites into the highly 
reactive form BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that 
is able to bind to DNA to form bulky DNA adducts. When 
unrepaired, DNA adducts can lead to mutations that initiate 
carcinogenesis. Therefore, bulky DNA adducts are markers for 
both the exposure to genotoxic aromatic compounds and the 
ability of the individual to metabolically activate carcinogens 
and to repair DNA damage (1). Nevertheless, individuals with 
similar exposures have highly different DNA adduct levels (2), 
which may in part be explained by genetic polymorphisms in 
genes involved in the process of DNA adduct formation and 
repair. These variations have been studied extensively and mul-
tiple genetic polymorphisms affecting BPDE-DNA adducts 
have been identified, including genes involved in metabolism 
(CYP1A1, GSTM1, GSTT1 (3–5)), DNA repair (ERCC1, XPD 
(6)) and oxidative stress (7).
We previously showed that single genetic polymorphisms are 
unable to adequately account for the inter-individual variation 
but rather by combinations of relevant genetic polymorphisms 
and the level of exposure (8). The level of exposure is often 
insufficiently characterised in large epidemiological studies that 
investigate the impact of genetic variation on DNA damage or 
disease, leading to misclassification and attenuation of under-
lying relationships. On the other hand, exposure can be well 
controlled in in vitro or ex vivo studies, offering the possibility 
to elucidate genotype–phenotype relationships and gene–gene 
interactions more reliably. Interestingly, the level of BPDE-
DNA adduct formation ex vivo in lymphocytes was related to 
lung cancer risks (9), further offering support for using ex vivo 
experiments to investigate sources of inter-individual variation 
in cancer susceptibility. Therefore, lymphocytes of healthy vol-
unteers were incubated with 1 µM BaP for 18 h. We assessed 
34 single nucleotide polymorphism (SNPs) based on a priori 
knowledge (10) and determined which SNPs were responsible 
for differences in BaP-related DNA adduct levels. One SNP 
in catalase (CAT, rs1001179) and one in CYP1B1 (rs1800440) 
had a significant impact on BaP-related DNA adducts forma-
tion and further experiments were performed to study geno-
type–phenotype relationships and gene–gene interactions in 
lung epithelial cells (A549) in which catalase was transiently 
knocked down by siRNA.
Materials and methods
Study population
The previously described study population consisted of 114 females and 54 
males, aged 18–45 with an average of 29 and 28 years for males and females, 
respectively (10). These healthy volunteers were recruited through adver-
tisements in local newspapers and were non-smokers and did not use medi-
cation (except for oral contraceptives by all female volunteers) or vitamin 
supplementation. Subjects were fully informed about the details of the study 
and gave their written informed consent. The Medical Ethical Committee of 
Maastricht University and the Academic Hospital Maastricht approved the 
protocol.
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Collection and treatment of samples
Venous blood samples were collected between 8 and 9 AM in 10 ml vac-
uum lithium heparin tubes (venoject II, Terumo-Europe, Leuren, Belgium). 
For isolation of lymphocytes, heparinised blood was 1:1 diluted with phos-
phate-buffered saline (PBS, pH 7.4) and layered on Lymphoprep™ (Axis-
shield, Oslo, Norway) in a leucosep tube (Greiner Bio-one, Frickenhausen, 
Germany). Lymphocytes were separated by 20 min 860g centrifugation at 
room temperature and subsequently washed and treated with 25 µM hydro-
gen peroxide for 1 h at 37°C or 1 µM BaP for 18 h at 37°C as described by 
Wilms et al. (10)
Comet assay
Following incubation with hydrogen peroxide, cell suspensions were diluted 
1:4 in 0.5% low melting-point agarose and added to microscope slides pre-
coated with a layer of 1.5% normal melting-point agarose and put at 4°C for 45 
min. Cells were lysed (0.25 M NaOH, 0.1 M EDTA, 0.01 M Tris, 2.5 M NaCl, 
1% Triton X-100 and 10% DMSO, adjusted to pH 10) for 1 h at 4°C, washed 
with PBS, placed in electrophoresis buffer (1 mM EDTA, 300 mM NaOH, pH 
13) for 40 min for denaturation and subsequently separated by electrophoresis 
for 30 min at 25 V and 300 mA. The slides were washed twice with PBS for 10 
min and stained with ethidium bromide (10 µg/ml) and visualised using a Zeiss 
Axioskop fluorescence microscope. About 50 randomly selected nuclei were 
analysed per slide using the Comet assay III software program (Perceptive 
Instruments, Havervill, UK).
Genotyping
DNA was isolated from lymphocytes by standard phenol extraction procedures. 
The Cancer SNP 500 database was used to obtain DNA sequences and allele 
frequencies (http://snp500cancer.nci.nih.gov) of 34 SNPs (Supplementary 
Table I, available at Mutagenesis Online). SNPs were analysed using a mul-
tiplex PCR method developed by Knaapen et al. (11) and further refined by 
Ketelslegers et al. (8). Genotyping of 10% of the samples was performed in 
duplicate to ensure reliability.
32P post-labeling of BaP-related DNA adducts
DNA adduct levels were determined according to the nuclease P1 enrich-
ment technique originally reported by Reddy and Randerath (12) with the 
modifications described by Godschalk et al. (13). Three standards with known 
BaP-related DNA adduct levels were analysed in parallel for quantification 
purposes. Adduct spots that chromatographed at the same position as the BaP-
related DNA adduct standards were considered to be derived from BaP and 
were quantified using Phosphor-Imaging technology (Fujifilm FLA-3000, 
Rotterdam, The Netherlands).
Cell culture and siRNA transfection
The human epithelial lung carcinoma cell line A549 obtained from the 
American Tissue Culture Collection (ATCC, Rockville, MD, USA) were cul-
tured in Dulbecco's modified Eagle's medium (Sigma, St. Louis, MO, USA) 
supplemented with 10% heat-inactivated fetal calf serum (FCS, Invitrogen, 
Breda, The Netherlands) and 1% penicillin/streptomycin (Sigma), and main-
tained at 37°C in a 5% CO2 atmosphere. Cells were seeded at 10% conflu-
ence 1 day before treatment in antibiotic free medium and maintained at 37°C 
in a 5% CO2 atmosphere. Cells were transfected with 10 nM siGENOME 
SMARTpool siRNA specific for human catalase (Dharmacon, Lafayette, CO, 
USA) using DharmaFECT (Dharmacon). The transfections were performed 
according to manufacturer’s instructions. After 24 h, the medium was removed 
and replaced with regular culture medium for a further 8 h.
Real-time quantitative PCR
RNA for real-time quantitative PCR was isolated from lymphocytes or A549 cells 
by standard phenol extraction procedures. The RNA samples were spectrophoto-
metrically quantified using Nanodrop 1000 (Thermo Scientific, Waltham, MA, 
USA). Complementary DNA (cDNA) synthesis was performed using the iScript 
cDNA Synthesis kit (Biorad, Veenendaal, The Netherlands) starting with 1 µg 
of RNA. The generated cDNA was diluted 25× in RNase free water. Real-time 
PCR was performed using the MyiQ Single Color RT–PCR detection system 
(Biorad) and Sensimix Sybr Green (Quantace, London, UK). 5 µl diluted cDNA 
and 0.3 µM primers (Supplementary Table II, available at Mutagenesis Online) 
in a total volume of 25 µl were used. Samples were amplified under the following 
conditions: 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 60°C for 
45 s. The PCR was checked for non-specific products by performing a melting 
curve analysis (65°C–95°C). Data were analysed using the MyiQ Software sys-
tem (Biorad) and were expressed as relative gene expression (fold increase) using 
the 2-ΔΔCt method. The stably expressed gene β-actin was included as reference.
Statistical analysis
Results are expressed as mean ± standard error of the mean. SPSS version 16 
for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. 
BaP-related DNA adducts were not normally distributed and were therefore 
log transformed before statistical analysis. To examine differences between 
the three groups of polymorphic genotypes (i.e. homozygous wild type, het-
erozygotes and homozygous variant), a one-way analysis of variance test with 
Bonferroni post hoc multiple comparison correction was used. Linear regres-
sion was used to assess relations. The two-way analysis of variance test with 
Bonferroni post hoc multiple comparison correction was used to examine the 
effect of catalase knockdown. Differences were considered to be statistically 
significant when P < 0.05.
Results
SNPs in CYP1B1 and catalase are linked to ex vivo BaP-
related DNA adduct formation
Of the 34 SNPs, we obtained (Supplementary Table I, available 
at Mutagenesis Online); only two were related to BaP-related 
DNA adduct levels ex vivo. These were the polymorphisms in 
CYP1B1 (rs1800440) and catalase (rs1001179). Individuals 
carrying one or both variant allele of CYP1B1-N453S showed 
a statistically significant lower amount of BaP-related DNA 
adducts compared with individuals that were homozygous 
for the wild-type allele (Figure  1A). Individuals carrying 
one or both variant alleles of CAT C-262T had higher levels 
of BaP-related DNA adducts compared with individuals that 
were homozygous for the wild-type allele (Figure 1B). Lowest 
Fig. 1. Modulation of ex vivo induced BaP-related DNA adducts by SNPs in 
catalase and CYP1B1. Lymphocytes of 168 volunteers were incubated with 
1 µM BaP for 18 h and DNA adducts were measured using 32P post-labeling. 
The effect of the (A) CYP1B1-N453S polymorphism and the (B) CAT-262C/T 
polymorphism on BaP-related DNA adduct formation was determined. DNA 
adduct data were log transformed and presented as mean ± standard error of 
the mean (n = 168, *P < 0.05, **P < 0.01).
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BaP-related DNA adduct levels were observed in subjects that 
carried the combined homozygous CYP1B1 variant alleles and 
the homozygous wild-type alleles for CAT.
Phenotypic effect of SNP in promoter region of CAT
As the SNP in catalase is located in the promoter region, 
we sought to determine whether gene expression would be 
affected. Therefore, mRNA levels were determined (Figure 2) 
in unexposed peripheral blood lymphocytes of 30 subjects 
selected on basis of their genotype (10 of each genotype). 
Individuals homozygous for the wild-type allele of CAT (CC) 
had ~1.9-fold lower catalase mRNA levels than individuals 
that were homozygous for the variant allele (P  <  0.001). To 
assess whether increased expression of CAT also resulted in a 
concomitant increased catalase activity, the ability to prevent 
single-strand breaks (SSB) induced by H2O2 was determined 
(Figure 3). To this end, lymphocytes were incubated with H2O2 
and a comet assay was performed to measure SSB. Samples 
from individuals that were homozygous for the wild-type allele 
of CAT (CC) had ~1.5-fold higher amount of SSB than samples 
from subjects carrying at least one T-allele (P < 0.001). This is 
consistent with the lower mRNA expression levels observed in 
lymphocytes of subjects carrying at least one T allele.
Expression of catalase strongly correlated with expression 
of CYP1B1
To further define how catalase expression effects BaP-related 
DNA adduct levels, catalase mRNA levels were correlated 
with the expression of CYP1B1 and a strong significant cor-
relation was observed (P  <  0.001, R  =  0.92, Figure  4). The 
genetic polymorphism in CAT, which regulates the level of 
gene expression of CAT, thus seems to co-regulate the expres-
sion of CYP1B1 in human lymphocytes. Indeed, the expres-
sion of CYP1B1 was approximately 2-fold higher in carriers of 
the CAT TT-genotype than in the CC-genotype subjects but this 
did not reach statistical significance (P = 0.08). No difference 
was observed between CYP1B1 mRNA expression of male and 
female volunteers (data not shown).
In vitro modulation of catalase expression alters CYP1B1 
mRNA levels
To further investigate the mechanism by which catalase affects 
CYP1B1 gene expression, A549 lung epithelial cells lines 
were used to investigate the effect of changing catalase gene 
expression on CYP1B1. A  statistically significant correlation 
in the expression of catalase and CYP1B1 was observed in 
unexposed cells (P < 0.001, R = 0.96, Figure 4). From the ex 
vivo observation, we hypothesised that knocking down the 
expression of catalase would also downregulate the expression 
of CYP1B1. After knockdown of catalase expression, only 
15% of the catalase mRNA remained following 24 h of 
siRNA treatment (Figure  5). The expected simultaneous 
downregulation of CYP1B1 gene expression was not observed. 
On the other hand, the removal of the siRNA resulted in the 
recovery of CAT expression, which coincided with a 2.2-fold 
upregulation of CYP1B1 expression (P < 0.001).
Downregulation of catalase is expected to increase intracel-
lular oxidative stress; the resulting activation of the nuclear 
erythroid 2-related factor 2 (Nrf2) pathway may be a potential 
Fig. 2. SNP in promoter region of catalase affects CAT expression. The 
effect of the CAT-262C/T polymorphism on catalase gene expression was 
determined in unexposed lymphocytes. Data are presented as fold increase 
compared with the C/C genotype (n = 30, 10 in each group, ***P < 0.001).
Fig. 3. CAT polymorphism reduces H2O2-induced SSBs. The effect of 
CAT-262C/T polymorphism on catalase phenotype was determined in H2O2-
exposed lymphocytes. Lymphocytes were incubated with 25 µM H2O2 for 1 h 
and SSBs were measured using the comet assay. Data are presented as mean ± 
standard error of the mean (n = 135, ***P < 0.001).
Fig. 4. Expression of catalase correlates strongly with expression of 
CYP1B1. mRNA levels of catalase and CYP1B1 were measured in unexposed 
lymphocytes, n = 30 (circle), and A549 cells, n = 9 (triangle). Data are 
presented as Ct value difference between CAT and the housekeeping gene. 
Regression line shown belongs to gene expression of lymphocytes but also fits 
the results in A549 cells.
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explanation for the initial lack of response in CYP1B1 expres-
sion since CYP1B1 expression is also known to be modulated 
by Nrf2 (14). Therefore, gene expression of the reporter gene 
NAD(P)H dehydrogenase quinone 1 (NQO1), which is regu-
lated via the Nrf2 pathway, was determined and interestingly 
a significant upregulation of NQO1 (~1.4-fold) was observed 
during catalase knockdown. This suggests that an activation 
of the Nrf2 pathway prevents CYP1B1 to be downregulated in 
parallel with catalase after its knockdown. On the other hand, 
the subsequent removal of the siRNA and resultant restora-
tion of catalase expression coincided with an upregulation of 
CYP1B1 expression. These in vitro studies confirm that cata-
lase may affect CYP1B1 gene expression.
Discussion
PAHs such as BaP are carcinogens that humans are unknow-
ingly and/or unavoidably exposed to on a daily basis. The 
ability of an individual to cope with these carcinogens may 
determine the risk of developing cancer. This intrinsic risk var-
ies within the population and genetic polymorphisms in genes 
such as those involved in BaP metabolism may be a source 
of this disparity. Previous studies showed that certain genetic 
polymorphisms are related to an increase in adduct formation 
(3,15). However, phenotypic effects of certain genetic poly-
morphisms are difficult to assess in epidemiological studies 
because exposure misclassification attenuates underlying rela-
tionships. Therefore, we exposed cells to a single compound to 
further elucidate genotype–phenotype relationships and report 
that genetic polymorphisms in catalase and CYP1B1 interact 
in determining the levels of BaP-related DNA adducts ex vivo.
Of the 34 polymorphisms investigated, only two resulted in a 
difference in BaP-related DNA adduct formation. The CYP1B1-
N453S polymorphism has previously been linked to altered 
cancer risks and aggressiveness of hormone-dependent cancers 
(16,17). This could be explained by the increased degradation 
rate of CYP1B1 and subsequent decreased CYP1B1 activity 
observed in individuals with the 453S allele (18). Decreased 
CYP1B1 activity can result in a decreased genotoxicity from 
estrogen metabolism (19). Interestingly, estrogen metabolism 
shows large overlap with the metabolism of PAH, such as BaP. 
CYP1B1 is also capable of metabolising BaP to its reactive 
metabolites. This metabolic activation is usually ascribed 
to CYP1A1 but the expression of CYP1A1 is minimal in 
lymphocytes. In our sample population, expression of CYP1A1 
was more than 18-fold lower than the expression of CYP1B1 
(data not shown). The CYP1B1-N453S variant alleles appear 
to be protective since individuals carrying one or two variant 
alleles had lower levels of BaP-related DNA adducts after ex 
vivo exposure to BaP (Figure 1).
The other polymorphism that influenced BaP-related DNA 
adduct formation in our population was catalase C-262T 
(rs1001179). Catalase reduces oxidative stress by catalysing 
the conversion of H2O2 into water and oxygen. The location of 
this polymorphism in the promoter suggests that it is involved 
in the regulation of catalase gene expression. Therefore, we 
measured catalase mRNA levels in lymphocytes from individu-
als carrying different alleles. The subjects carrying the variant 
allele had higher expression of CAT compared with subjects 
carrying the wild-type allele. This finding is in concordance 
with Forsberg et al. (20) who showed that the C/T polymor-
phism in the promoter region of the CAT gene induced the tran-
scriptional activity of the promoter. The induced catalase gene 
expression also coincide with the induced activity of catalase 
in subjects carrying at least one T-allele since they had lower 
levels of SSB induced by H2O2.
The observation that the expression of CYP1B1 was approx-
imately 2-fold higher in carriers of the CAT TT-genotype than 
in the CC-genotype subjects and because a strong correlation 
was observed between the expression of CAT and the expres-
sion of CYP1B1 led to the hypothesis that the genetic poly-
morphism in CAT would affect DNA adduct formation induced 
by BaP via its effect on CYP1B1 expression. Previous studies 
in hepatoma cells have shown that oxidative stress decreased 
the expression of CYP1A1, which like CYP1B1 is a member 
of the CYP1 family (21–23). This oxidative stress–mediated 
repression was mediated by a nuclear factor 1 (NF1) binding 
to the promoter region of these CYPs (22). The expression of 
CYP1A1 and CYP1B1 is activated by binding of a ligand, such 
as BaP, to the aryl hydrocarbon receptor (AhR). Upon ligand 
binding, AhR translocates into the nucleus and dimerises with 
the AhR nuclear translocator (ARNT), which can bind to the 
TNGCGTG consensus sequence in the xenobiotic-responsive 
elements of target genes (24). This AhR-ARNT complex syn-
ergises with other transcription factors including NF1, thereby 
activating gene expression, suggesting that high levels of H2O2 
could also result in reduced transcription of CYP1B1. We found 
a strong correlation between catalase expression and CYP1B1 
expression (R > 0.92) in lymphocytes and A549 cells. Thus, we 
hypothesised that the SNP in catalase determines the amount of 
CYP1B1 and the SNP in CYP1B1 subsequently determines the 
activity of the enzyme.
To further study the combined effect of CAT and CYP1B1 
polymorphisms on BaP-related DNA adduct formation, we 
transiently knocked down catalase by siRNA. Indeed, the 
recovery of CAT expression after removal of the siRNA 
coincided with increasing levels of CYP1B1 mRNA lev-
els. However, the effective knockdown of catalase expres-
sion to less than 15% of the original level did not result in 
the expected decrease of CYP1B1 gene expression. This 
suggests that under circumstances of oxidative stress, other 
mechanisms are capable of keeping CYP1B1 gene expression 
intact. A  likely candidate was the Nrf2 that when activated 
Fig. 5. CYP1B1 mRNA levels are increased upon recovery of catalase 
mRNA levels 8 h after a transient knockdown. mRNA levels of catalase, 
CYP1B1 and NQO1 in A549 were measured after no treatment (white), 
24 h of catalase siRNA (striped), 24 h of catalase siRNA followed by 8 h 
recovery without siRNA (black). Data are presented as mean ± standard error 
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significantly induced AhR, CYP1A1 and CYP1B1 transcrip-
tions in mouse embryonic fibroblasts (14). In response to oxi-
dative stress, Nrf2 is activated and upregulates antioxidant and 
detoxifying genes, including NQO1 (25). In our study, the 
increase in NQO1 mRNA levels suggests that the knockdown 
of catalase is indeed related to increased oxidative stress levels 
and activation of Nrf2. The opposing effects of both NF1 and 
Nrf2 eventually resulted in an initial unchanged CYP1B1 gene 
expression. However, when catalase mRNA levels started to 
increase after removal of the siRNA, oxidative stress quickly 
decreased and the Nrf2 was deactivated (since NQO1 expres-
sion went back to baseline levels). We speculate that as a result 
of the restored expression of catalase, CYP1B1 expression fur-
ther increased and was over-compensated (>2-fold increased 
expression). These in vitro studies confirm that catalase affects 
CYP1B1 gene expression.
We propose a model in which the genetic polymorphism in 
the promotor region of CAT-262C→T determines the amount 
of intracellular oxidative stress, which co-regulates the expres-
sion of CYP1B1 by reducing the amount of H2O2 present in the 
cells. Oxidative stress would inactivate or activate relevant tran-
scription factors (NF1 and Nrf2). The genetic polymorphisms 
in CYP1B1 subsequently modulates BaP metabolism ex vivo 
in lymphocytes. Thus, the SNP in CAT determines the amount 
of CYP1B1, whereas the SNP in CYP1B1 determines its activ-
ity. These ex vivo data indicate that inter-individual variations 
in DNA adduct levels depend on gene–gene interactions, 
which need further attention for application in in vivo studies. 
Understanding gene–gene interactions allows the identification 
of relevant combinations of SNPs to assess an individual’s can-
cer susceptibility.
Supplementary data
Supplementary Tables I and II are available at Mutagenesis 
Online.
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